Cargando…
Future therapy of portal hypertension in liver cirrhosis – a guess
In patients with chronic liver disease, portal hypertension is driven by progressive fibrosis and intrahepatic vasoconstriction. Interruption of the initiating and perpetuating etiology—mostly leading to necroinflammation—is possible for several underlying causes, such as autoimmune hepatitis, hepat...
Autores principales: | Sauerbruch, Tilman, Trebicka, Jonel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty of 1000 Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191223/ https://www.ncbi.nlm.nih.gov/pubmed/25374673 http://dx.doi.org/10.12703/P6-95 |
Ejemplares similares
-
Managing portal hypertension in patients with liver cirrhosis
por: Sauerbruch, Tilman, et al.
Publicado: (2018) -
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy
por: Iwakiri, Yasuko, et al.
Publicado: (2021) -
Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction
por: Sauerbruch, Tilman, et al.
Publicado: (2021) -
Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023) -
Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
por: Kreisel, Wolfgang, et al.
Publicado: (2021)